title: [Changes in nonspecific suppressor factors in the serum of gastric cancer patients after surgery and immunochemotherapy].
abstract: After curative surgery for gastric cancers judged macroscopically to be at stage 2 or 3, patients were divided into 4 groups by randomization. As the basic treatment, patients were given one-shot Mitomycin and Tegafur as maintenance therapy for 8 months (group A). PSK (group B), OK-432 (group C) or both PSK and OK-432 (group D) were added to the treatment of group A for 8 months. Sera were obtained from these groups of patients at 4 weeks and 3, 6, 9 and 12 months after surgery. In all of these groups, values of IAP increased slightly at 4 weeks but decreased at 3 months and were maintained at such a level by 12 months. On the other hand, suppressive effects of such sera on the blastogenesis of murine spleen cells in response to PHA varied among these group. In groups A and C, the suppressive effect of sera increased after surgery and was detected continuously by 12 months. In groups B and D, in contrast, the suppressive effect disappeared from 3 to 12 months. The rise and fall of such a suppressive effect of sera may reflect the mode of action of PSK.
authors.forename: K
authors.initials: K
authors.lastname: Nomoto
authors.forename: S
authors.initials: S
authors.lastname: Tsuru
authors.forename: Y
authors.initials: Y
authors.lastname: Awane
authors.forename: H
authors.initials: H
authors.lastname: Kamei
authors.forename: H
authors.initials: H
authors.lastname: Ishibiki
authors.forename: M
authors.initials: M
authors.lastname: Sekiguchi
authors.forename: R
authors.initials: R
authors.lastname: Tamada
authors.forename: T
authors.initials: T
authors.lastname: Toge
authors.forename: T
authors.initials: T
authors.lastname: Nakajima
mesh_terms: D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D010844:Picibanil / Q000008:administration & dosage; D011184:Postoperative Period; D011509:Proteoglycans / Q000008:administration & dosage; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000276:immunology* / Q000601:surgery / Q000628:therapy; D013491:Suppressor Factors, Immunologic / Q000032:analysis* / Q000502:physiology; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D008937:Mitomycins; D011509:Proteoglycans; D013491:Suppressor Factors, Immunologic; D005641:Tegafur; D010844:Picibanil; C010770:polysaccharide-K; D016685:Mitomycin